Latest Biosecurity News

Nexsen has paused its StrepSure clinical programme after an interim review identified performance improvements needed before a US FDA submission, pushing the target timetable back by roughly one quarter. Its shares were then suspended pending an announcement about a potentially material contract for an additional device.

Nexsen Limited (ASX:NXN) reported a 30% rise in net loss to $6.55 million for FY26, driven by ongoing investment in its Group B Streptococcus rapid diagnostic and Asia-Pacific growth initiatives following its October 2025 IPO.

Farm Pride Foods Ltd reported a 16% revenue increase to $118.3 million and a 53% jump in net profit to $10.2 million for FY26, underpinned by operational improvements and strategic capital investments.

Atlas Pearls Ltd (ASX: ATP) faced a tough FY26 with revenue down 42% to $25.8 million and a net loss of $7.9 million, driven by lower pearl quality and softer market conditions. Despite this, the company seeded a record number of oysters and declared a fully franked final dividend of 0.45 cents per share.

Inghams Group delivered modest revenue growth in FY26 but saw net profit collapse amid cost pressures and tax disputes. Executive short-term incentives were forfeited, while the company declared a fully franked dividend and outlined a cautious FY27 outlook.

Farm Pride Foods reported a $10.143 million operating cash inflow for FY26, driven by steady operational improvements and strategic investments in farm capacity despite lower egg prices in H2.

Island Pharmaceuticals has presented encouraging Phase 2a results for its dengue antiviral ISLA-101, demonstrating safety, effective blood concentrations, and meaningful viral load reductions at the Asia Dengue Summit.

Nexsen Limited has cleared a major FDA regulatory hurdle for its StrepSure rapid Group B Streptococcus test, confirmed a clear 510(k) submission pathway, and secured over A$1.7 million in non-dilutive grants to expand clinical validation and market rollout in Asia-Pacific and neonatal diagnostics.

Nexsen Limited is advancing its rapid Group B Streptococcus test, StrepSure®, with a clear FDA submission timeline and early market entries across Asia-Pacific and emerging regions.

Farm Pride Foods reported a robust net cash inflow of $32.56 million for the December quarter despite mounting pricing pressures and increased industry egg volumes. The company is doubling down on capital expenditure and operational improvements to sustain efficiency.

Nexsen Limited has won a $500,000 non-dilutive grant to extend its rapid Group B Streptococcus diagnostic technology into neonatal care, opening a significant new market opportunity.

Island Pharmaceuticals has been granted a key US patent for Galidesivir, extending intellectual property protection through 2031 for treating filoviridae viruses including Marburg and Ebola. This milestone aligns with the company’s clinical development strategy and recent FDA regulatory progress.